Cargando…

Super-enhanced MARCO variant drives triple-negative breast cancer progression

Detalles Bibliográficos
Autores principales:	Lin, Weei-Chin, Lin, Fang-Tsyr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897437/ https://www.ncbi.nlm.nih.gov/pubmed/36469785 http://dx.doi.org/10.1073/pnas.2217953119

Ejemplares similares

Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression
por: Yang, Yun-Song, et al.
Publicado: (2022)

Super-enhancer acquisition drives oncogene expression in triple negative breast cancer
por: Raisner, Ryan, et al.
Publicado: (2020)

Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
por: Huang, Hao, et al.
Publicado: (2021)

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)

TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation
por: Lin, Fang-Tsyr, et al.
Publicado: (2016)

Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy
por: Chowdhury, Pinki, et al.
Publicado: (2014)

On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
por: Boudghene-Stambouli, Fadia, et al.
Publicado: (2022)

RNA nanoparticles for targeted therapies of triple-negative breast cancers
por: Danai, Leyla, et al.
Publicado: (2023)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2022)

DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors
por: Folly-Kossi, Helena, et al.
Publicado: (2023)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies
por: MacDonald, Isaiah, et al.
Publicado: (2022)

14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer
por: Garan, Lidija A. Wilhelms, et al.
Publicado: (2022)

Associations of Warfarin Use with Risks of Ischemic Cerebrovascular Events and Major Bleeding in Patients with Hyperthyroidism-Related Atrial Fibrillation
por: Liu, Sian-De, et al.
Publicado: (2022)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy
por: Stefanski, Casey D., et al.
Publicado: (2022)

RARRES2’s impact on lipid metabolism in triple-negative breast cancer: a pathway to brain metastasis
por: Shubhra, Quazi T. H.
Publicado: (2023)

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer
por: Huang, Shang-Pen, et al.
Publicado: (2017)

Triple negative breast cancer: Pitfalls and progress
por: Zagami, Paola, et al.
Publicado: (2022)

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
por: Rizzo, Alessandro, et al.
Publicado: (2022)

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer
por: Mekky, Radwa Y., et al.
Publicado: (2023)

An androgen receptor regulated gene score is associated with epithelial to mesenchymal transition features in triple negative breast cancers
por: Rajarajan, Savitha, et al.
Publicado: (2023)

Loss of ANCO1 Expression Regulates Chromatin Accessibility and Drives Progression of Early-Stage Triple-Negative Breast Cancer
por: Yuan, Meng, et al.
Publicado: (2023)

C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple‐negative breast cancer
por: Liao, Li, et al.
Publicado: (2023)

Comment to “Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis”
por: Altundag, Kadri
Publicado: (2016)

Role of eIF4A1 in triple‐negative breast cancer stem‐like cell‐mediated drug resistance
por: Raman, Dayanidhi, et al.
Publicado: (2020)

Cancer-Associated Fibroblasts Autophagy Enhances Progression of Triple-Negative Breast Cancer Cells
por: Wang, Mengchuan, et al.
Publicado: (2017)

Super enhancer-driven core transcriptional regulatory circuitry crosstalk with cancer plasticity and patient mortality in triple-negative breast cancer
por: Shi, Wensheng, et al.
Publicado: (2023)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Comment on “comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian women” by Saleh et al.
por: Brody, James P.
Publicado: (2021)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

MicroRNAs in regulation of triple-negative breast cancer progression
por: Piasecka, Dominika, et al.
Publicado: (2018)

Triple-negative breast cancer molecular subtyping and treatment progress
por: Yin, Li, et al.
Publicado: (2020)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_72h9ju54j5urb63nv3dn81io23